LISTING OF THE CLAIMS

A listing of the pending claims is provided below.

1. (Previously Presented) An antibody that binds to human DC-SIGN, the antibody comprising:

a light chain variable region comprising: (i) a light chain CDR1 comprising amino acids 24 to 34 of SEQ ID NO:10; (ii) a light chain CDR2 comprising amino acids 50 to 56 of SEQ ID NO:10; and (iii) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:45; and

a heavy chain variable region comprising: (iv) a heavy chain CDR1 comprising amino acids 31 to 36 of SEQ ID NO:18; (v) a heavy chain CDR2 comprising amino acids 51 to 66 of SEQ ID NO:18; and (vi) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:49.

2. (Original) The antibody of claim 1 further comprising a peptide attached to the antibody.

3. (Original) The antibody of claim 2 wherein the peptide comprises an antigen.

4. (Original) The antibody of claim 3 wherein the antigen comprises a cancer antigen.

5-6. (Cancelled).

7. (Original) A composition comprising an antibody as in claim 1 and a pharmaceutically acceptable carrier.

8. (Original) An antibody as in claim 1 wherein the antibody is a humanized antibody.

9. (Original) An antibody as in claim 1 wherein the antibody is an scFv.

10-12. (Cancelled).

13. (Previously Presented) An antibody as in claim 1, wherein the light chain variable region comprises the entire amino acid sequence depicted in SEQ ID NO:10.

14-18. (Cancelled).

19. (Previously Presented) An antibody in accordance with claim 1, the antibody being capable of effectively blocking for a cell that expresses DC-SIGN at least one of the following: (i) binding of a virus selected from the group consisting of HIV, HCV, Ebola, SARS, CMV, Sindbis and Dengue to the cell, (ii) infection of the cell by a virus selected from the group consisting of HIV, HCV, Ebola, SARS, CMV, Sindbis and Dengue, (iii) transmission of a virus selected from the group consisting of HIV, HCV, Ebola, SARS, CMV, Sindbis and Dengue from the cell to another cell, (iv) binding of a bacterium selected from the group consisting of Helicobacter pylori, Klebsiella pneumoniae, Mycobacterium tuberculosis and Mycobacterium bovis to the cell, (v) infection of the cell by a bacterium selected from the group consisting of Helicobacter pylori, Klebsiella pneumoniae, Mycobacterium tuberculosis and Mycobacterium bovis, (vi) transmission of a bacterium selected from the group consisting of Helicobacter pylori, Klebsiella pneumoniae, Mycobacterium tuberculosis and Mycobacterium bovis from the cell to another cell, (vii) binding of a parasite selected from the group consisting of Leishmania pifanoi and Schistosoma mansoni to the cell, (viii) infection of the cell by a parasite selected from the group consisting of Leishmania pifanoi and Schistosoma mansoni, or (ix) transmission of a parasite selected from the group consisting of Leishmania pifanoi and Schistosoma mansoni from the cell to another cell.

20. (Original) An antibody in accordance with claim 19, wherein the antibody also binds to L-SIGN.

21-30. (Cancelled).

31. (Previously Presented) A diagnostic agent for a tumor characterized by increased DC-SIGN expression comprising the antibody of claim 1.

32. (Original) A diagnostic kit comprising the diagnostic agent of claim 31.

33-47. (Cancelled).

48. (Previously Presented) The antibody of claim 1, wherein the heavy chain variable region comprises the entire amino acid sequence depicted in SEQ ID NO:18.

49. (Previously Presented) The antibody of claim 1, wherein the light chain variable region comprises the entire amino acid sequence depicted in SEQ ID NO:10 and the heavy chain variable region comprises the entire amino acid sequence depicted in SEQ ID NO:18.

50. (Previously Presented) The antibody of claim 1, wherein the antibody is a whole antibody.

51. (Previously Presented) The antibody of claim 1, wherein the antibody is an antibody fragment selected from the group consisting of an Fab fragment and an $F(ab')_2$ fragment.

52. (Previously Presented) The antibody of claim 4, wherein the antigen is selected from the group consisting of gp100, g250, p53, MAGE, BAGE, GAGE, MART 1, tyrosinase related protein 11, and tyrosinase related protein.